enGene Therapeutics Inc.
For the period ended Jul 31, 2026. Filed Sep 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jul 31, 2026 · Filed Sep 8, 2026
ENGN$1.75+4.2%Stored close · as of Nov 6, 2026
What changed in Risk Factors?
Read the current filingComparison unavailable
The extracted section boundaries could not be preserved reliably for this comparison. Open the source filing to review the Item.
Earlier comparable report: 10-Q, period ended 2026-04-30, filed 2026-06-15. Read that report
Unavailable is not the same as unchanged.